Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Algernon’s business model is based on drug re-purposing, finding new uses for know drugs





 

Bullboard - Investor Discussion Forum Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc > Last Patient enrolled recovers in 10 days, great news
View:
Post by Alex1967 on Dec 24, 2020 5:30pm

Last Patient enrolled recovers in 10 days, great news

Final patient was enrolled on Nov 30, two weeks of treatment and 2 weeks of follow-up, this means that the patient was released from the hospital on Dec 10th, which is 4 to 5 days sooner than the average. The drug is working, at least the last patient. ( recovered 4 to 5 days faster than the average.)
 
VANCOUVER, British Columbia, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the last patient from the Phase 2b part of its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, has now completed treatment as well as the required two-week follow up.
Comment by talisman47 on Dec 24, 2020 10:25pm
Where did you see that the patient was releaswed from hospital ?? I read it that the last patient was on medication for 15 days and then there was a two week follow up to analyse data. It would be fantastic if they were released 4-5 days faster than average. Please advise. Thanks
Comment by Pandora on Dec 24, 2020 11:27pm
From the NR: "The last patient from Algernon Pharmaceuticals Inc.'s phase 2b part of its multinational phase 2b/3 human study of NP-120 (ifenprodil) for the treatment of COVID-19 has now completed treatment, as well as the required two-week follow up."
Comment by Alex1967 on Dec 25, 2020 7:53am
On Nov. 30,  Algernon is pleased to announce that the final patient has been enrolled in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. Dec. 24, 2020  Algernon is pleased to announce that the last patient from the Phase 2b part of its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, has now ...more  
Comment by talisman47 on Dec 25, 2020 2:49pm
Could be as you say, however, I don't think that if a patient completes a 15 day trial period that it means they went home after it. The trial was just to collect information for  15 days, the patient may have been well enough to get out of ICU, or they may have had to continue to stay in ICU after the Algernon 15 day trial completed with them. If a patient got out of ICU 4-5 days faster ...more  
Comment by Alex1967 on Dec 25, 2020 10:11pm
Happy Holidays Nick. I hope I am right as well, have a good feeling about this.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

Connect with C.AGN


CEO Clips: DMT Clinical Trial

CEO Q&A Interview with Chris Moreau

Investor Presentation

Download the latest Investor Presentaion

Algernon Highlights: The Watchlist

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Investment Opportunity

The Algernon Value Proposition



  • Advancing new drug treatments for billion dollar global disease markets.
  • Re-purposed compounds have a much lower risk of failing in human trials as a result of safety issues.
  • Conducting multiple phase II clinical trials.
  • Highly capital efficient business model.
  • Experienced management team & globally recognized medical advisory board.

Facebook